CryoLife's cardiac patch approved in US
This article was originally published in Clinica
Executive Summary
The CryoPatch SG pulmonary human cardiac patch developed by CryoLife has received 510(k) clearance from the US FDA for the repair of the right ventricular outflow tract. This surgery is commonly performed in children with congenital heart defects – a market worth $15m in the US. Launch is set for the third quarter of 2009. The patch is produced using the Kennesaw, Georgia company's SynerGraft technology, which removes allogeneic donor cells and cellular remnants from donated tissue, avoiding immunological rejection.
You may also be interested in...
ITF Has A Fight On Its Hands In Duchenne
The group’s new muscular dystrophy pill seems unlikely to cut into Sarepta’s sales.
AbbVie Needs To Freshen Up
With half of its 2023 sales coming from aging blockbusters like Humira and Botox, AbbVie needs new blood.
AstraZeneca Pays $2bn To Keep Up With The Joneses
Bristol Myers Squibb and Lilly have recently done billion-dollar radiopharmaceuticals deals, and now the UK group wants a piece of the market. But can it make its Fusion fusion work?